LH
Labcorp Holdings Inc. NYSE$255.84
Mkt Cap $21.4B
52w Low $235.81
34.6% of range
52w High $293.72
50d MA $271.22
200d MA $268.54
P/E (TTM)
24.3x
EV/EBITDA
13.7x
P/B
2.5x
Debt/Equity
0.8x
ROE
10.2%
P/FCF
17.3x
RSI (14)
—
ATR (14)
—
Beta
0.98
50d MA
$271.22
200d MA
$268.54
Avg Volume
640.4K
About
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 4.09 | 4.25 | +3.9% | 257.14 | +2.9% | -0.1% | -0.5% | — | — | — | — | — |
| Feb 17, 2026 | BMO | 3.95 | 4.07 | +3.0% | 282.63 | -1.7% | -2.1% | -1.4% | -0.1% | +0.0% | +0.9% | -6.6% | — |
| Oct 28, 2025 | BMO | 4.13 | 4.18 | +1.2% | 275.66 | -3.9% | -5.8% | -10.0% | -8.5% | -7.9% | -6.5% | -2.5% | — |
| Jul 24, 2025 | BMO | 4.17 | 4.35 | +4.3% | 250.51 | +6.4% | +6.9% | +5.8% | +4.5% | +4.5% | +5.3% | +10.2% | — |
| Apr 29, 2025 | BMO | 3.74 | 3.84 | +2.7% | 229.60 | -3.4% | +4.7% | +5.0% | +5.1% | +7.9% | +7.5% | +7.5% | — |
| Feb 6, 2025 | BMO | 3.39 | 3.45 | +1.8% | 249.99 | +1.2% | -0.9% | -1.5% | -2.0% | -1.9% | -3.5% | -2.3% | — |
| Oct 24, 2024 | BMO | 3.47 | 3.50 | +0.9% | 219.90 | +2.6% | +4.6% | +4.0% | +3.4% | +3.7% | +4.8% | +9.7% | — |
| Aug 1, 2024 | BMO | 3.78 | 3.94 | +4.2% | 215.44 | +2.1% | +8.3% | +9.5% | +6.1% | +4.8% | +1.8% | +6.6% | — |
| Apr 25, 2024 | BMO | 3.48 | 3.68 | +5.7% | 207.94 | -1.5% | -4.6% | -4.6% | -1.8% | -3.2% | -3.2% | -5.7% | — |
| Feb 15, 2024 | BMO | 3.29 | 3.30 | +0.3% | 228.11 | -0.5% | -2.6% | -5.0% | -5.5% | -4.5% | -4.5% | -8.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $269.17 | $271.95 | +1.0% | +2.1% | +1.5% | -3.1% | -1.9% | -0.1% |
| Feb 24 | Piper Sandler | Maintains | Neutral → Neutral | — | $285.30 | $285.20 | -0.0% | +0.6% | -0.9% | +0.8% | +1.3% | +0.4% |
| Feb 18 | Baird | Maintains | Outperform → Outperform | — | $276.67 | $279.37 | +1.0% | +0.8% | +2.1% | +2.2% | +3.1% | +3.8% |
| Feb 18 | JP Morgan | Maintains | Overweight → Overweight | — | $276.67 | $279.37 | +1.0% | +0.8% | +2.1% | +2.2% | +3.1% | +3.8% |
| Feb 6 | JP Morgan | Maintains | Overweight → Overweight | — | $278.23 | $280.00 | +0.6% | -0.4% | -1.5% | +2.3% | +4.2% | -0.0% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $246.64 | $246.84 | +0.1% | +2.5% | +5.9% | +8.7% | +7.8% | +8.6% |
| Oct 29 | UBS | Maintains | Buy → Buy | — | $259.69 | $259.00 | -0.3% | -4.4% | -2.8% | -2.2% | -0.7% | -2.8% |
| Oct 17 | Mizuho | Maintains | Outperform → Outperform | — | $283.71 | $284.68 | +0.3% | +0.8% | +2.5% | +0.1% | -0.3% | +0.1% |
| Oct 17 | UBS | Maintains | Buy → Buy | — | $283.71 | $284.68 | +0.3% | +0.8% | +2.5% | +0.1% | -0.3% | +0.1% |
| Oct 3 | Evercore ISI | Maintains | Outperform → Outperform | — | $279.44 | $279.96 | +0.2% | -0.9% | -1.6% | +0.1% | -0.7% | -0.6% |
Recent Filings
8-K
Labcorp Holdings Inc. -- 8-K Filing
Labcorp Holdings reported Q1 2026 results and raised full-year guidance, signaling confidence in its laboratory services business performance and providing updated investor expectations for 2026.
Apr 30
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
LabCorp declares a $0.72 quarterly dividend, demonstrating confidence in cash generation and shareholder returns, which typically supports stock valuation for income-focused investors.
Apr 9
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
LH scheduled Q1 2026 earnings release for April 30, 2026, signaling normal operational transparency; investors should monitor results for revenue growth and margin performance in diagnostic/laboratory services.
Mar 31
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
Failure to meet covenant requirements could force accelerated repayment of debt, creating liquidity risk and potentially triggering financial distress if the company cannot refinance quickly.
Mar 20
8-K
Labcorp Holdings Inc. -- 8-K Filing
Labcorp exceeded expectations in 2025 with 7% revenue growth and double-digit adjusted EPS expansion, signaling operational strength entering 2026 despite ongoing healthcare sector challenges.
Feb 17
8-K · 5.02
!!! Very High
Labcorp Holdings Inc. -- 8-K 5.02: Executive Change
Labcorp Holdings appointed John H. Sampson as director effective February 9, 2026, potentially bringing fresh expertise to the board's oversight of the clinical laboratory company's operations.
Feb 9
Data updated apr 25, 2026 7:05pm
· Source: massive.com